Share

CLINICAL TRIAL SEARCH RESULTS

NEW SEARCH
 Number: GOG 0076HH Principal Investigator: Mutch, David
Title: A Limited Access Phase I/II Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Velaparib) (IND #77840) in the Treatment of Advanced, Persistent, or Recurrent Carcinomas of Cervix
Description: The purpose of the first part of this study (called Phase I) is to test how safe ABT-888 is and to determine the appropriate dose of ABT-888 to be used in the Phase II part of the study. If you enter the study on the Phase I portion, the dose of ABT-888 you will receive will depend on when you enter...MORE
___________________________________________________________________________________________________
 Number: ACRIN 6682 Principal Investigator: Dehdashti, Farrokh
Title: Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer
___________________________________________________________________________________________________
 Number: 201104322 Principal Investigator: Grigsby, Perry
Title: FDG Tumor Heterogeneity during Chemoradiation as a Predictor of Response to Concurrent Radiation Therapy and Chemotherapy in Patients with Cervical Cancer
Description: The purpose of this research study is to see if positron emission tomography (PET imaging) with 18Ffluorodeoxyglucose (FDG – a radioactive form of sugar) can help doctors determine which patients will respond best to traditional treatment versus those that need more aggressive therapy to prevent the...MORE
___________________________________________________________________________________________________
 Number: 201105400 Principal Investigator: Mutch, David
Title: Formation of a Tissue Bank for Gynecologic Malignancies
Description: The purpose of this study is to collect specimens (i.e., tissue obtained during surgery and/or blood) and related information from women who are undergoing surgery for a gynecologic condition. Specimens and related information that are collected for this research study will be used for future cance...MORE
___________________________________________________________________________________________________